Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias

被引：1
|
作者：
Montastruc, Francois [1 ,2 ,3 ]
de Canecaude, Claire [1 ,2 ]
机构：
[1] Toulouse Univ Hosp CHU, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, Toulouse, France
[2] Toulouse Univ Hosp, Ctr Invest Clin 1436, Team PEPSS Pharmacol Populat cohorteS & biobanqueS, Toulouse, France
[3] Toulouse Univ Hosp, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, 37 Allees Jules Guesde, F-31000 Toulouse, France
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 11期
关键词：
D O I：
10.1093/cid/ciad089
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2044 / 2045
页数：2
相关论文
共 50 条
  • [11] Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis
    Ayman Al Jurdi
    Christopher El Mouhayyar
    Orhan Efe
    Anushya Jeyabalan
    Leonardo V. Riella
    Journal of Nephrology, 2024, 37 : 141 - 147
  • [12] Single-Center Review of Tixagevimab-Cilgavimab Use in Solid Organ Transplant Recipients
    Shaikh, S.
    Davoudi, R.
    Kawewat-Ho, P.
    Cartus, R.
    Morado, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S660 - S661
  • [13] REAL-WORLD EFFECTIVENESS AND SAFETY OF TIXAGEVIMAB-CILGAVIMAB: A TARGET TRIAL EMULATION STUDY
    Yan, V
    Yang, Y.
    Wan, E. Y. F.
    Yiu, H. H. E.
    Wong, I. C. K.
    Chan, E. W.
    VALUE IN HEALTH, 2023, 26 (12) : S221 - S221
  • [14] Tixagevimab-Cilgavimab for Breakthrough COVID-19 Prevention in Dialysis Patients: A Prospective Study
    Sritippayawan, Suchai
    Boongird, Sarinya
    Srithongkul, Thatsaphan
    Sethakarun, Sethanant
    Bruminhent, Jackrapong
    Kiertiburanakul, Sasisopin
    Nongnuch, Arkom
    Kitiyakara, Chagriya
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [15] Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study
    Yan, Vincent Ka Chun
    Yang, Yu
    Wan, Eric Yuk Fai
    Lai, Francisco Tsz Tsun
    Chui, Celine Sze Ling
    Li, Xue
    Wong, Carlos King Ho
    Hung, Ivan Fan Ngai
    Lau, Chak Sing
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    DRUG SAFETY, 2024, 47 (10) : 1025 - 1037
  • [16] Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis
    Al Jurdi, Ayman
    El Mouhayyar, Christopher
    Efe, Orhan
    Jeyabalan, Anushya
    Riella, Leonardo V.
    JOURNAL OF NEPHROLOGY, 2024, 37 (01) : 141 - 147
  • [17] Tixagevimab-cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study
    Boongird, Sarinya
    Srithongkul, Thatsaphan
    Sethakarun, Sethanant
    Bruminhent, Jackrapong
    Kiertiburanakul, Sasisopin
    Nongnuch, Arkom
    Kitiyakara, Chagriya
    Sritippayawan, Suchai
    CLINICAL KIDNEY JOURNAL, 2024, 17 (11)
  • [18] Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: concern for immortal time bias effect
    Riggs, Julie M.
    Charya, V. Ananth
    Eberlein, Michael H.
    Reed, Robert M.
    Saharia, Kapil K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (03) : 450 - 450
  • [19] Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence
    Manuela Altieri
    Rosario Domenico Melisi
    Miriana Conte
    Rocco Capuano
    Giovanna Donnarumma
    Elena Grimaldi
    Nicola Coppola
    Stefania De Pascalis
    Mario Risi
    Alessandro d’Ambrosio
    Alvino Bisecco
    Antonio Gallo
    Neurological Sciences, 2023, 44 : 4107 - 4110
  • [20] Tixagevimab-cilgavimab as pre-exposure prophylactic treatment against SARS-CoV-2 in kidney transplantation patients
    Gonzalez-Blas, Luis Bravo
    Garcia, Natalia Menendez
    Prada, Maria Fernandez
    Fraile, Maria Gago
    Fernandez, Maria Luisa Suarez
    Cano, Natalia Ridao
    NEFROLOGIA, 2024, 44 (03): : 396 - 401
12345